montelukast
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Eosinophilic Gastroenteritis
Conditions
Eosinophilic Gastroenteritis, Dyspepsia
Trial Timeline
Sep 1, 2005 → Dec 1, 2006
NCT ID
NCT00148603About montelukast
montelukast is a pre-clinical stage product being developed by Merck for Eosinophilic Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00148603. Target conditions include Eosinophilic Gastroenteritis, Dyspepsia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01618929 | Approved | Completed |
| NCT01027806 | Approved | Terminated |
| NCT00492102 | Phase 1 | Completed |
| NCT00559546 | Approved | Completed |
| NCT00721240 | Approved | Completed |
| NCT00148603 | Pre-clinical | Completed |
| NCT00934713 | Approved | Completed |
| NCT00116324 | Phase 3 | Completed |
Competing Products
20 competing products in Eosinophilic Gastroenteritis